Brief: Lumiradx Latest Cost Reduction Program Continues Progress Toward Operating Cash Flow Breakeven By The End Of 2023
Dec 19 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX LATEST COST REDUCTION PROGRAM CONTINUES PROGRESS
TOWARD
OPERATING CASH FLOW BREAKEVEN BY THE END OF 2023
* LUMIRADX LTD - MOST RECENT REDUCTIONS ARE EXPECTED TO
LOWER THE
COMPANY’S ANNUALIZED EXPENSES IN 2023 BY $20 MILLION
* LUMIRADX LTD - FULL BENEFIT OF THE COST REDUCTIONS IS
EXPECTED
BEFORE THE END OF THE FIRST QUARTER OF 2023
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing